Abstracts tagged "Anakinra"

Abstract Number: 135 • 2012 ACR/ARHP Annual Meeting
A Pilot Study of the Efficacy of IL1 Blockade by Anakinra in Acute Calcific Periarthritis of the Rotator Cuff
Pascal Zufferey¹, Melanie Faucherre², Pierre A. Varisco¹, Berengere Aubry Sr.¹, Isabelle Fabreguet³ and Alexander K. So Sr.¹, ¹Dal/Rhu, CHUV, Lausanne, Switzerland, ²Dal /Rhu, CHUV, Lausanne, Switzerland, ³CHUV, Lausanne, Switzerland
Background/Purpose: Calcific periarthritis of rotator cuff can induce acute and severe shoulder pain and is accompnied by signs of acute inflammation. The calcific deposits are…
Abstract Number: 2655 • 2012 ACR/ARHP Annual Meeting
Rapid and Effective Response to Immunosuppression in Treating Macrophage Activation Syndrome Associated with a Heterozygous Dominant Negative Mutation in RAB27a Leading to Decreased Cytolytic Activity
Randy Q. Cron¹, Mingce Zhang², Christina J. Bemrich-Stolz² and Timothy Beukelman¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Pediatrics, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is an often fatal disorder of infancy resulting from homozygous mutations in proteins involved in cytolysis (e.g. MUNC13-4, RAB27a, Perforin 1,…
Abstract Number: 2656 • 2012 ACR/ARHP Annual Meeting
Elevated Serum Follistatin-Like Protein 1 Suggests an Interleukin-1 Independent Pathway for Inflammation in Patients with Cryopyrin Associated Periodic Syndromes
Mark Gorelik¹, Daniel Bushnell², Raphaela T. Goldbach-Mansky³, Hal M. Hoffman⁴ and Raphael Hirsch⁵, ¹Pediatric Rheumatology/Floor 3, Univ of Pittsburgh Med Ctr Children's Hospital, Pittsburgh, PA, ²Division of Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁴Division of Allergy, Immunology and Rheumatology, University of California at San Diego, La Jolla, CA, ⁵Department of Pediatrics,, University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: Cryopyrin associated periodic syndromes (CAPS) are a group of IL-1β mediated autoinflammatory diseases characterized by fever, urticaria and conjunctivitis, and in severe cases, CNS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].